Cwm LLC Buys 66,639 Shares of Johnson & Johnson $JNJ

Cwm LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 12.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 605,826 shares of the company’s stock after acquiring an additional 66,639 shares during the quarter. Cwm LLC’s holdings in Johnson & Johnson were worth $112,332,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson during the 2nd quarter valued at $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson in the third quarter valued at about $28,000. Semmax Financial Advisors Inc. lifted its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the period. GFG Capital LLC bought a new position in Johnson & Johnson during the 2nd quarter worth about $35,000. Finally, 1248 Management LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $48,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several research reports. Barclays upped their price target on shares of Johnson & Johnson from $176.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Sanford C. Bernstein upped their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. Guggenheim increased their target price on Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Argus set a $210.00 price target on Johnson & Johnson in a research report on Wednesday, October 15th. Finally, Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $210.25.

Johnson & Johnson Stock Down 0.1%

Shares of JNJ stock opened at $207.54 on Friday. The stock’s fifty day moving average price is $199.67 and its 200 day moving average price is $181.03. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.18. The company has a market cap of $500.02 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.